Airways  ||| S:0 E:8 ||| NNP
allergic  ||| S:8 E:17 ||| JJ
inflammation  ||| S:17 E:30 ||| NN
and  ||| S:30 E:34 ||| CC
L.  ||| S:34 E:37 ||| NNP
reuterii  ||| S:37 E:46 ||| JJ
treatment  ||| S:46 E:56 ||| NN
in  ||| S:56 E:59 ||| IN
asthmatic  ||| S:59 E:69 ||| JJ
children  ||| S:69 E:78 ||| NNS
Recently ||| S:78 E:86 ||| RB
,  ||| S:86 E:88 ||| ,
it  ||| S:88 E:91 ||| PRP
has  ||| S:91 E:95 ||| VBZ
been  ||| S:95 E:100 ||| VBN
hypothesized  ||| S:100 E:113 ||| VBN
that  ||| S:113 E:118 ||| IN
the  ||| S:118 E:122 ||| DT
oral  ||| S:122 E:127 ||| JJ
administration  ||| S:127 E:142 ||| NN
of  ||| S:142 E:145 ||| IN
specific  ||| S:145 E:154 ||| JJ
live  ||| S:154 E:159 ||| JJ
probiotic  ||| S:159 E:169 ||| JJ
strains  ||| S:169 E:177 ||| NNS
may  ||| S:177 E:181 ||| MD
have  ||| S:181 E:186 ||| VB
therapeutic  ||| S:186 E:198 ||| JJ
potential  ||| S:198 E:208 ||| NN
in  ||| S:208 E:211 ||| IN
the  ||| S:211 E:215 ||| DT
treatment  ||| S:215 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
allergic  ||| S:228 E:237 ||| JJ
inflammation ||| S:237 E:249 ||| NN
.  ||| S:249 E:251 ||| .
The  ||| S:251 E:255 ||| DT
aim  ||| S:255 E:259 ||| NN
of  ||| S:259 E:262 ||| IN
this  ||| S:262 E:267 ||| DT
study  ||| S:267 E:273 ||| NN
was  ||| S:273 E:277 ||| VBD
to  ||| S:277 E:280 ||| TO
evaluate  ||| S:280 E:289 ||| VB
the  ||| S:289 E:293 ||| DT
effect  ||| S:293 E:300 ||| NN
of  ||| S:300 E:303 ||| IN
the  ||| S:303 E:307 ||| DT
oral  ||| S:307 E:312 ||| JJ
L.  ||| S:312 E:315 ||| NNP
reuteri  ||| S:315 E:323 ||| VBD
DSM  ||| S:323 E:327 ||| NNP
17938  ||| S:327 E:333 ||| CD
administration  ||| S:333 E:348 ||| NN
( ||| S:348 E:349 ||| -LRB-
1X108CFU ||| S:349 E:357 ||| NNP
) ||| S:357 E:358 ||| -RRB-
,  ||| S:358 E:360 ||| ,
in  ||| S:360 E:363 ||| IN
airways  ||| S:363 E:371 ||| JJ
allergic  ||| S:371 E:380 ||| JJ
inflammation  ||| S:380 E:393 ||| NN
in  ||| S:393 E:396 ||| IN
mild  ||| S:396 E:401 ||| JJ
persistent  ||| S:401 E:412 ||| JJ
asthmatic  ||| S:412 E:422 ||| JJ
children ||| S:422 E:430 ||| NNS
.  ||| S:430 E:432 ||| .
In  ||| S:432 E:435 ||| IN
this  ||| S:435 E:440 ||| DT
DBPC  ||| S:440 E:445 ||| NNP
randomized  ||| S:445 E:456 ||| JJ
study  ||| S:456 E:462 ||| NN
we  ||| S:462 E:465 ||| PRP
selected  ||| S:465 E:474 ||| VBD
50  ||| S:474 E:477 ||| CD
children  ||| S:477 E:486 ||| NNS
( ||| S:486 E:487 ||| -LRB-
6-14  ||| S:487 E:492 ||| CD
years  ||| S:492 E:498 ||| NNS
old ||| S:498 E:501 ||| JJ
) ||| S:501 E:502 ||| -RRB-
,  ||| S:502 E:504 ||| ,
affected  ||| S:504 E:513 ||| VBN
by  ||| S:513 E:516 ||| IN
mild  ||| S:516 E:521 ||| JJ
persistent  ||| S:521 E:532 ||| JJ
asthma  ||| S:532 E:539 ||| NN
( ||| S:539 E:540 ||| -LRB-
GINA  ||| S:540 E:545 ||| NNP
step  ||| S:545 E:550 ||| NN
2 ||| S:550 E:551 ||| CD
)  ||| S:551 E:553 ||| -RRB-
and  ||| S:553 E:557 ||| CC
allergic  ||| S:557 E:566 ||| JJ
to  ||| S:566 E:569 ||| TO
HDM ||| S:569 E:572 ||| NNP
.  ||| S:572 E:574 ||| .
At  ||| S:574 E:577 ||| IN
the  ||| S:577 E:581 ||| DT
run-in  ||| S:581 E:588 ||| JJ
period  ||| S:588 E:595 ||| NN
( ||| S:595 E:596 ||| -LRB-
T-2 ||| S:596 E:599 ||| NNP
) ||| S:599 E:600 ||| -RRB-
,  ||| S:600 E:602 ||| ,
the  ||| S:602 E:606 ||| DT
children  ||| S:606 E:615 ||| NNS
were  ||| S:615 E:620 ||| VBD
submitted  ||| S:620 E:630 ||| VBN
to  ||| S:630 E:633 ||| TO
medical  ||| S:633 E:641 ||| JJ
examination ||| S:641 E:652 ||| NN
,  ||| S:652 E:654 ||| ,
prick  ||| S:654 E:660 ||| JJ
tests  ||| S:660 E:666 ||| NNS
for  ||| S:666 E:670 ||| IN
the  ||| S:670 E:674 ||| DT
main  ||| S:674 E:679 ||| JJ
respiratory  ||| S:679 E:691 ||| JJ
allergens ||| S:691 E:700 ||| NN
,  ||| S:700 E:702 ||| ,
spirometry  ||| S:702 E:713 ||| NN
and  ||| S:713 E:717 ||| CC
children  ||| S:717 E:726 ||| NNS
asthma  ||| S:726 E:733 ||| JJ
control  ||| S:733 E:741 ||| NN
test  ||| S:741 E:746 ||| NN
( ||| S:746 E:747 ||| -LRB-
C-ACT ||| S:747 E:752 ||| NNP
) ||| S:752 E:753 ||| -RRB-
.  ||| S:753 E:755 ||| .
We  ||| S:755 E:758 ||| PRP
selected  ||| S:758 E:767 ||| VBD
only  ||| S:767 E:772 ||| RB
the  ||| S:772 E:776 ||| DT
children  ||| S:776 E:785 ||| NNS
with  ||| S:785 E:790 ||| IN
well  ||| S:790 E:795 ||| RB
controlled  ||| S:795 E:806 ||| VBN
asthma  ||| S:806 E:813 ||| NN
( ||| S:813 E:814 ||| -LRB-
C-ACT  ||| S:814 E:820 ||| NNP
> ||| S:820 E:821 ||| CD
19  ||| S:821 E:824 ||| CD
and  ||| S:824 E:828 ||| CC
FEV1 ||| S:828 E:832 ||| CD
>  ||| S:832 E:834 ||| CD
80 ||| S:834 E:836 ||| CD
% ||| S:836 E:837 ||| NN
) ||| S:837 E:838 ||| -RRB-
.  ||| S:838 E:840 ||| .
After  ||| S:840 E:846 ||| IN
two  ||| S:846 E:850 ||| CD
weeks  ||| S:850 E:856 ||| NNS
( ||| S:856 E:857 ||| -LRB-
T0 ||| S:857 E:859 ||| NNP
)  ||| S:859 E:861 ||| -RRB-
the  ||| S:861 E:865 ||| DT
children  ||| S:865 E:874 ||| NNS
were  ||| S:874 E:879 ||| VBD
allocated  ||| S:879 E:889 ||| VBN
into  ||| S:889 E:894 ||| IN
two  ||| S:894 E:898 ||| CD
groups ||| S:898 E:904 ||| NNS
,  ||| S:904 E:906 ||| ,
the  ||| S:906 E:910 ||| DT
FeNO  ||| S:910 E:915 ||| NN
was  ||| S:915 E:919 ||| VBD
measured  ||| S:919 E:928 ||| VBN
and  ||| S:928 E:932 ||| CC
the  ||| S:932 E:936 ||| DT
breath  ||| S:936 E:943 ||| NN
condensate  ||| S:943 E:954 ||| NNS
was  ||| S:954 E:958 ||| VBD
collected ||| S:958 E:967 ||| VBN
.  ||| S:967 E:969 ||| .
Group  ||| S:969 E:975 ||| NNP
A  ||| S:975 E:977 ||| NNP
children  ||| S:977 E:986 ||| NNS
were  ||| S:986 E:991 ||| VBD
treated  ||| S:991 E:999 ||| VBN
with  ||| S:999 E:1004 ||| IN
the  ||| S:1004 E:1008 ||| DT
placebo  ||| S:1008 E:1016 ||| NN
( ||| S:1016 E:1017 ||| -LRB-
5  ||| S:1017 E:1019 ||| CD
drops  ||| S:1019 E:1025 ||| NNS
per  ||| S:1025 E:1029 ||| IN
day ||| S:1029 E:1032 ||| NN
)  ||| S:1032 E:1034 ||| -RRB-
and  ||| S:1034 E:1038 ||| CC
Group  ||| S:1038 E:1044 ||| NNP
B  ||| S:1044 E:1046 ||| NNP
children  ||| S:1046 E:1055 ||| NNS
with  ||| S:1055 E:1060 ||| IN
L.  ||| S:1060 E:1063 ||| NNP
reuteri  ||| S:1063 E:1071 ||| NNS
( ||| S:1071 E:1072 ||| -LRB-
108CFU  ||| S:1072 E:1079 ||| FW
=5  ||| S:1079 E:1082 ||| FW
drops  ||| S:1082 E:1088 ||| FW
per  ||| S:1088 E:1092 ||| FW
day ||| S:1092 E:1095 ||| NN
)  ||| S:1095 E:1097 ||| -RRB-
for  ||| S:1097 E:1101 ||| IN
60  ||| S:1101 E:1104 ||| CD
days ||| S:1104 E:1108 ||| NNS
.  ||| S:1108 E:1110 ||| .
After  ||| S:1110 E:1116 ||| IN
the  ||| S:1116 E:1120 ||| DT
treatment  ||| S:1120 E:1130 ||| NN
period  ||| S:1130 E:1137 ||| NN
( ||| S:1137 E:1138 ||| -LRB-
T1 ||| S:1138 E:1140 ||| NNP
) ||| S:1140 E:1141 ||| -RRB-
,  ||| S:1141 E:1143 ||| ,
all  ||| S:1143 E:1147 ||| DT
patients  ||| S:1147 E:1156 ||| NNS
were  ||| S:1156 E:1161 ||| VBD
evaluated  ||| S:1161 E:1171 ||| VBN
by  ||| S:1171 E:1174 ||| IN
medical  ||| S:1174 E:1182 ||| JJ
examination ||| S:1182 E:1193 ||| NN
,  ||| S:1193 E:1195 ||| ,
C-ACT ||| S:1195 E:1200 ||| NNP
,  ||| S:1200 E:1202 ||| ,
spirometry ||| S:1202 E:1212 ||| NN
,  ||| S:1212 E:1214 ||| ,
FeNO  ||| S:1214 E:1219 ||| JJ
measurement  ||| S:1219 E:1231 ||| NN
and  ||| S:1231 E:1235 ||| CC
exaled  ||| S:1235 E:1242 ||| JJ
breath  ||| S:1242 E:1249 ||| NN
condensate  ||| S:1249 E:1260 ||| NN
analysis ||| S:1260 E:1268 ||| NN
.  ||| S:1268 E:1270 ||| .
The  ||| S:1270 E:1274 ||| DT
FeNO  ||| S:1274 E:1279 ||| JJ
values  ||| S:1279 E:1286 ||| NNS
showed  ||| S:1286 E:1293 ||| VBD
a  ||| S:1293 E:1295 ||| DT
significant  ||| S:1295 E:1307 ||| JJ
reduction  ||| S:1307 E:1317 ||| NN
( ||| S:1317 E:1318 ||| -LRB-
p=0,045 ||| S:1318 E:1325 ||| NNP
)  ||| S:1325 E:1327 ||| -RRB-
in  ||| S:1327 E:1330 ||| IN
L.  ||| S:1330 E:1333 ||| NNP
reuteri  ||| S:1333 E:1341 ||| JJ
group  ||| S:1341 E:1347 ||| NN
but  ||| S:1347 E:1351 ||| CC
not  ||| S:1351 E:1355 ||| RB
in  ||| S:1355 E:1358 ||| IN
the  ||| S:1358 E:1362 ||| DT
placebo  ||| S:1362 E:1370 ||| JJ
group  ||| S:1370 E:1376 ||| NN
at  ||| S:1376 E:1379 ||| IN
the  ||| S:1379 E:1383 ||| DT
end  ||| S:1383 E:1387 ||| NN
of  ||| S:1387 E:1390 ||| IN
the  ||| S:1390 E:1394 ||| DT
treatment  ||| S:1394 E:1404 ||| NN
( ||| S:1404 E:1405 ||| -LRB-
T1 ||| S:1405 E:1407 ||| NNP
) ||| S:1407 E:1408 ||| -RRB-
.  ||| S:1408 E:1410 ||| .
Furthermore ||| S:1410 E:1421 ||| RB
,  ||| S:1421 E:1423 ||| ,
the  ||| S:1423 E:1427 ||| DT
cytokines  ||| S:1427 E:1437 ||| JJ
exam  ||| S:1437 E:1442 ||| NN
showed  ||| S:1442 E:1449 ||| VBD
an  ||| S:1449 E:1452 ||| DT
increase  ||| S:1452 E:1461 ||| NN
in  ||| S:1461 E:1464 ||| IN
IL-10  ||| S:1464 E:1470 ||| CD
levels  ||| S:1470 E:1477 ||| NNS
( ||| S:1477 E:1478 ||| -LRB-
p  ||| S:1478 E:1480 ||| RB
less  ||| S:1480 E:1485 ||| JJR
than  ||| S:1485 E:1490 ||| IN
0.05 ||| S:1490 E:1494 ||| CD
)  ||| S:1494 E:1496 ||| -RRB-
and  ||| S:1496 E:1500 ||| CC
a  ||| S:1500 E:1502 ||| DT
significant  ||| S:1502 E:1514 ||| JJ
reduction  ||| S:1514 E:1524 ||| NN
in  ||| S:1524 E:1527 ||| IN
IL-2  ||| S:1527 E:1532 ||| CD
levels  ||| S:1532 E:1539 ||| NNS
( ||| S:1539 E:1540 ||| -LRB-
p  ||| S:1540 E:1542 ||| RB
less  ||| S:1542 E:1547 ||| JJR
than  ||| S:1547 E:1552 ||| IN
0.05 ||| S:1552 E:1556 ||| CD
)  ||| S:1556 E:1558 ||| -RRB-
only  ||| S:1558 E:1563 ||| RB
in  ||| S:1563 E:1566 ||| IN
L.  ||| S:1566 E:1569 ||| NNP
reuteri  ||| S:1569 E:1577 ||| JJ
group  ||| S:1577 E:1583 ||| NN
at  ||| S:1583 E:1586 ||| IN
T1 ||| S:1586 E:1588 ||| CD
.  ||| S:1588 E:1590 ||| .
No  ||| S:1590 E:1593 ||| DT
significant  ||| S:1593 E:1605 ||| JJ
differences  ||| S:1605 E:1617 ||| NNS
in  ||| S:1617 E:1620 ||| IN
FEV1  ||| S:1620 E:1625 ||| CD
values  ||| S:1625 E:1632 ||| NNS
and  ||| S:1632 E:1636 ||| CC
C-ACT  ||| S:1636 E:1642 ||| JJ
score  ||| S:1642 E:1648 ||| NN
were  ||| S:1648 E:1653 ||| VBD
found  ||| S:1653 E:1659 ||| VBN
in  ||| S:1659 E:1662 ||| IN
both  ||| S:1662 E:1667 ||| DT
groups ||| S:1667 E:1673 ||| NNS
.  ||| S:1673 E:1675 ||| .
In  ||| S:1675 E:1678 ||| IN
conclusion ||| S:1678 E:1688 ||| NN
,  ||| S:1688 E:1690 ||| ,
these  ||| S:1690 E:1696 ||| DT
data  ||| S:1696 E:1701 ||| NNS
showed  ||| S:1701 E:1708 ||| VBD
that  ||| S:1708 E:1713 ||| IN
L.  ||| S:1713 E:1716 ||| NNP
reuteri  ||| S:1716 E:1724 ||| NNS
( ||| S:1724 E:1725 ||| -LRB-
108  ||| S:1725 E:1729 ||| CD
CFU ||| S:1729 E:1732 ||| NNP
)  ||| S:1732 E:1734 ||| -RRB-
was  ||| S:1734 E:1738 ||| VBD
effective  ||| S:1738 E:1748 ||| JJ
in  ||| S:1748 E:1751 ||| IN
reducing  ||| S:1751 E:1760 ||| VBG
bronchial  ||| S:1760 E:1770 ||| JJ
inflammation  ||| S:1770 E:1783 ||| NN
in  ||| S:1783 E:1786 ||| IN
asthmatic  ||| S:1786 E:1796 ||| JJ
children ||| S:1796 E:1804 ||| NNS
.  ||| S:1804 E:1806 ||| .
No  ||| S:1806 E:1809 ||| DT
significant  ||| S:1809 E:1821 ||| JJ
effect  ||| S:1821 E:1828 ||| NN
was  ||| S:1828 E:1832 ||| VBD
found  ||| S:1832 E:1838 ||| VBN
on  ||| S:1838 E:1841 ||| IN
FEV1  ||| S:1841 E:1846 ||| CD
values  ||| S:1846 E:1853 ||| NNS
and  ||| S:1853 E:1857 ||| CC
C-ACT  ||| S:1857 E:1863 ||| JJ
score ||| S:1863 E:1868 ||| NN
,  ||| S:1868 E:1870 ||| ,
probably  ||| S:1870 E:1879 ||| RB
because  ||| S:1879 E:1887 ||| IN
we  ||| S:1887 E:1890 ||| PRP
selected  ||| S:1890 E:1899 ||| VBD
children  ||| S:1899 E:1908 ||| NNS
with  ||| S:1908 E:1913 ||| IN
well  ||| S:1913 E:1918 ||| RB
controlled  ||| S:1918 E:1929 ||| VBN
asthma ||| S:1929 E:1935 ||| NN
.  ||| S:1935 E:1937 ||| .
